About Mevalonate kinase
Mevalonate kinase (MVK) is a protein
from Homo sapiens identified by UniProt accession
Q03426, 396 residues long.
MolForge cross-references it against 0 known binders and
241 disease associations.
Target properties
| Protein name | Mevalonate kinase |
| UniProt accession | Q03426 |
| Gene | MVK |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (241)
Diseases linked to this target (Open Targets).
- hyperimmunoglobulinemia D with periodic fever · score 0.85
- mevalonic aciduria · score 0.84
- disseminated superficial actinic porokeratosis · score 0.67
- Vitamin B12-responsive methylmalonic acidemia type cblB · score 0.55
- methylmalonic aciduria, cblB type · score 0.55
- neurodegenerative disease · score 0.53
- autoinflammatory syndrome · score 0.52
- genetic disorder · score 0.47
- retinitis pigmentosa · score 0.37
- mevalonate kinase deficiency · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q03426-F1 | alphafold | PREDICTED | 92.24 | — |
Amino-acid sequence (396 residues)
MLSEVLLVSA PGKVILHGEH AVVHGKVALA VSLNLRTFLR LQPHSNGKVD LSLPNIGIKR AWDVARLQSL DTSFLEQGDV TTPTSEQVEK LKEVAGLPDD CAVTERLAVL AFLYLYLSIC RKQRALPSLD IVVWSELPPG AGLGSSAAYS VCLAAALLTV CEEIPNPLKD GDCVNRWTKE DLELINKWAF QGERMIHGNP SGVDNAVSTW GGALRYHQGK ISSLKRSPAL QILLTNTKVP RNTRALVAGV RNRLLKFPEI VAPLLTSIDA ISLECERVLG EMGEAPAPEQ YLVLEELIDM NQHHLNALGV GHASLDQLCQ VTRARGLHSK LTGAGGGGCG ITLLKPGLEQ PEVEATKQAL TSCGFDCLET SIGAPGVSIH SATSLDSRVQ QALDGL
Explore Mevalonate kinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets